NO991358L - Anvendelse av sibutramin-analoger for Õ forebygge utvikling av diabetes - Google Patents

Anvendelse av sibutramin-analoger for Õ forebygge utvikling av diabetes

Info

Publication number
NO991358L
NO991358L NO991358A NO991358A NO991358L NO 991358 L NO991358 L NO 991358L NO 991358 A NO991358 A NO 991358A NO 991358 A NO991358 A NO 991358A NO 991358 L NO991358 L NO 991358L
Authority
NO
Norway
Prior art keywords
diabetes
development
prevent
sibutramine
analogues
Prior art date
Application number
NO991358A
Other languages
English (en)
Norwegian (no)
Other versions
NO991358D0 (no
Inventor
Clifford James Bailey
Robert Brian Jones
Helen Cristine Jackson
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of NO991358D0 publication Critical patent/NO991358D0/no
Publication of NO991358L publication Critical patent/NO991358L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrotherapy Devices (AREA)
NO991358A 1996-09-21 1999-03-19 Anvendelse av sibutramin-analoger for Õ forebygge utvikling av diabetes NO991358L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619757.9A GB9619757D0 (en) 1996-09-21 1996-09-21 Chemical process
PCT/EP1997/005039 WO1998011884A1 (en) 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes

Publications (2)

Publication Number Publication Date
NO991358D0 NO991358D0 (no) 1999-03-19
NO991358L true NO991358L (no) 1999-03-19

Family

ID=10800326

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991358A NO991358L (no) 1996-09-21 1999-03-19 Anvendelse av sibutramin-analoger for Õ forebygge utvikling av diabetes

Country Status (26)

Country Link
US (3) US6174925B1 (enExample)
EP (1) EP0927028A1 (enExample)
JP (1) JP2001503737A (enExample)
KR (1) KR20000048501A (enExample)
CN (1) CN1237905A (enExample)
AU (1) AU724488B2 (enExample)
BG (1) BG64473B1 (enExample)
BR (1) BR9711517A (enExample)
CA (1) CA2266401C (enExample)
CZ (1) CZ93699A3 (enExample)
GB (1) GB9619757D0 (enExample)
HR (1) HRP970505A2 (enExample)
HU (1) HUP9904026A3 (enExample)
ID (1) ID18320A (enExample)
IL (1) IL128850A (enExample)
MY (1) MY116150A (enExample)
NO (1) NO991358L (enExample)
NZ (1) NZ334580A (enExample)
PL (1) PL332305A1 (enExample)
RU (1) RU2245709C2 (enExample)
SK (1) SK31999A3 (enExample)
TR (1) TR199900618T2 (enExample)
TW (1) TW580385B (enExample)
UA (1) UA64726C2 (enExample)
WO (1) WO1998011884A1 (enExample)
ZA (1) ZA978450B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
DE69929996T2 (de) * 1998-06-30 2006-11-16 Takeda Pharmaceutical Co. Ltd. Pharmazeutisches mittel zur behandlung von diabetes
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
TR200101333T2 (tr) * 1998-11-12 2001-10-22 Smithkline Beecham P.L.C. Bir ensülin sensitizörü ve başka bir anti-diyabetik maddenin değiştirilmiş salımı için farmasötik terkip.
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
AR018699A1 (es) 1999-06-01 2001-11-28 Procter & Gamble Metodo para el tratamiento de la perdida del cabello el cual comprende administrar una composicion que comprende un compuesto el cual no afecta al corazon
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
WO2004030663A1 (en) * 2002-10-05 2004-04-15 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
TW200517127A (en) * 2003-08-07 2005-06-01 Sb Pharmco Inc Novel composition
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
ES2556244T3 (es) * 2003-10-31 2016-01-14 Takeda Pharmaceutical Company Limited Preparación sólida que comprende pioglitazona, glimepirida y un éster de ácido graso de polioxietilensorbitán
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
JP5432526B2 (ja) * 2006-01-06 2014-03-05 サノビオン ファーマシューティカルズ インク モノアミン再取り込み阻害剤としてのシクロアルキルアミン
RU2462451C2 (ru) 2006-09-15 2012-09-27 Ривайва Фармасьютикалс, Инк. Способ получения, способы применения и композиции циклоалкилметиламинов
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
EP2083867A1 (en) * 2006-11-22 2009-08-05 SK Chemicals, Co., Ltd. Inclusion complex of sibutramine and beta-cyclodextrin
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
EP4029444A1 (en) 2009-07-02 2022-07-20 Dexcom, Inc. Analyte sensor
MX355543B (es) 2010-08-13 2018-04-20 Aileron Therapeutics Inc Star Macrociclos peptidomiméticos.
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
IN2014MN01407A (enExample) 2011-12-30 2015-07-03 Reviva Pharmaceuticals Inc
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
SG11201404648PA (en) 2012-02-15 2014-09-26 Aileron Therapeutics Inc Peptidomimetic macrocycles
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1995010292A1 (en) 1993-10-14 1995-04-20 Biomedica California, Inc. Diabetes treatment and prophylaxis
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
MY116150A (en) 2003-11-28
CA2266401A1 (en) 1998-03-26
US6617360B1 (en) 2003-09-09
AU724488B2 (en) 2000-09-21
PL332305A1 (en) 1999-08-30
SK31999A3 (en) 1999-12-10
TR199900618T2 (xx) 1999-06-21
CN1237905A (zh) 1999-12-08
TW580385B (en) 2004-03-21
IL128850A0 (en) 2000-01-31
JP2001503737A (ja) 2001-03-21
GB9619757D0 (en) 1996-11-06
WO1998011884A1 (en) 1998-03-26
AU4774097A (en) 1998-04-14
CZ93699A3 (cs) 1999-08-11
HUP9904026A3 (en) 2000-07-28
HUP9904026A2 (hu) 2000-05-28
HRP970505A2 (en) 1998-08-31
IL128850A (en) 2003-07-31
ID18320A (id) 1998-03-26
EP0927028A1 (en) 1999-07-07
ZA978450B (en) 1999-03-19
UA64726C2 (uk) 2004-03-15
KR20000048501A (ko) 2000-07-25
NO991358D0 (no) 1999-03-19
NZ334580A (en) 2000-09-29
CA2266401C (en) 2007-01-30
US6174925B1 (en) 2001-01-16
BG64473B1 (bg) 2005-04-30
RU2245709C2 (ru) 2005-02-10
BG103277A (en) 2000-01-31
BR9711517A (pt) 1999-08-24
US20040077730A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
NO991358D0 (no) Anvendelse av sibutramin-analoger for Õ forebygge utvikling av diabetes
EE03832B1 (et) Heptapeptiidanaloogid
DE69739216D1 (de) Der Entwicklung von konditionierten Reflexen angepasstes System
ID17829A (id) Bahan perekar yang sensisitif terhadap tekanan
DE69826158D1 (de) Inspektionsgerät für das Aussehen von Kapseln
KR970706248A (ko) 불화된 유기화합물 제조방법(the preparation of fluorinated organic compounds)
EP0996458A4 (en) SANDRAMYCIN ANALOG
DE59701512D1 (de) Mehrprozessor-zentraleinheit
NO20001847D0 (no) Ny anvendelse av forbindelser for anti-kløe-aktivitet
DE69707612D1 (de) Aminobenzylamin enthaltende Kautschukmischung
ID22437A (id) Unit bilah pengaduk
DE3878868D1 (de) Generator fuer periodische zeitsignale des fractaltyps.
TR199500812A2 (tr) Elektrokimyasal ölcümlerdeki veya elektrokimyasal ölcümlerle ilgili gelismeler.
NO972278D0 (no) Fluorerte vitamin D3-analoger
NO964376D0 (no) Skosåle
DE69626799D1 (de) Navigationseinheit
NO20005507D0 (no) Spylerenseapparat
FI973826L (fi) Suoritettavat ohjelmat
ID24694A (id) Pemakaian bentuk zat-zat sebagai katalis untuk pembuatan kaprolaktam
ID22787A (id) Nitro-benzamida berguna sebagai zat anti - arritimia
DE69730060D1 (de) Organische-Inorganische Entwicklerzusammensetzung
KR960019736U (ko) 구두바닥의 구조
KR980004719U (ko) 모니터의 미끄럼 방지구조
ITAQ970012A1 (it) Soluzione per risolvere definitivamente la sudorazione dei piedi
KR960033885U (ko) 자동차 앞유리의 부착구조

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application